First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Conclusions: Pem + CT seemed to be more effective first-line regimen for advanced NSCLC with wild-type EGFR or ALK, especially for patients with NSCC. However, limitations of the study including methodological quality and immature OS data need to be considered.
PMID: 31463119 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Databases & Libraries | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Science | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology | Yervoy